Lacosamide is indicated to treat partial-onset seizures. It is also used with other medicines to treat primary generalized tonic-clonic seizures.

The product will be manufactured at the group’s formulation manufacturing facility in Moraiya, Ahmedabad (India).

Lacosamide Tablets had annual sales of $249 million in the United States (IQVIA Dec. Oct. 2023). The group now has 384 approvals and has so far filed over 448 ANDAs since the commencement of the filing process in FY 2003-04.

Zydus Lifesciences is a discovery-driven, global lifesciences company that discovers, develops, manufactures, and markets a broad range of healthcare therapies.

The company consolidated net profit surged 53.2% to Rs 800.7 crore in Q2 FY24 as compared with Rs 522.5 crore posted in Q2 FY23. Revenue from operations rose 9.1% YoY to Rs 4,368.8 crore during the quarter ended 30 September 2023.

The scrip rose 0.42% to currently trade at Rs 646.20 on the BSE on Friday.